Show notes
Dr. Brian Rini and Professor Tom Powles ask David McDermott about how he chooses between ipilimumab/nivolumab or axitinib/pebrolizumab intreatment options
Dr. Brian Rini and Professor Tom Powles ask David McDermott about how he chooses between ipilimumab/nivolumab or axitinib/pebrolizumab intreatment options